<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00084669</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000365502</org_study_id>
    <secondary_id>MGH-DFCI-02311</secondary_id>
    <secondary_id>DFCI-02311</secondary_id>
    <nct_id>NCT00084669</nct_id>
  </id_info>
  <brief_title>Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer</brief_title>
  <official_title>Targeting Insomnia to Enhance Hot Flush Treatment in Women Receiving Therapy for Breast Cancer or Breast Cancer Risk-Reduction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <brief_summary>
    <textblock>
      RATIONALE: Venlafaxine may be effective in relieving hot flashes caused by hormone therapy.&#xD;
      Giving venlafaxine with zolpidem (a sleeping pill) may improve sleep and quality of life in&#xD;
      women who are receiving hormone therapy for treatment or prevention of breast cancer.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying giving venlafaxine together with zolpidem&#xD;
      to see how well it works compared to venlafaxine alone in relieving hot flashes and&#xD;
      associated sleep disorders in women who are receiving hormone therapy to treat or prevent&#xD;
      breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the effect of venlafaxine or another serotonin-reuptake inhibitor with vs&#xD;
           without zolpidem, in terms of sleep continuity, in women with breast cancer or at high&#xD;
           risk for developing breast cancer who experience hot flushes and associated sleep&#xD;
           disorders.&#xD;
&#xD;
        -  Compare quality of life in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are&#xD;
      stratified by concurrent use of serotonin-reuptake inhibitors (SRI).&#xD;
&#xD;
        -  Stratum 1 (no concurrent SRI): Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
             -  Arm I: Patients receive oral venlafaxine once daily and oral zolpidem once daily&#xD;
                for 5 weeks*.&#xD;
&#xD;
             -  Arm II: Patients receive oral venlafaxine once daily and oral placebo once daily&#xD;
                for 5 weeks*.&#xD;
&#xD;
        -  Stratum 2 (concurrently on SRI): Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
             -  Arm I: Patients receive oral zolpidem once daily for 5 weeks*.&#xD;
&#xD;
             -  Arm II: Patients receive oral placebo once daily for 5 weeks*. NOTE: *After 5 weeks&#xD;
                of study treatment, patients in stratum 1 may taper or continue venlafaxine over 2&#xD;
                weeks (for a total duration of venlafaxine use of 7 weeks); patients in arm I of&#xD;
                both strata may taper or continue zolpidem over 1 week (for a total duration of&#xD;
                zolpidem use of 6 weeks); continuation or tapering of drugs in both arms occurs in&#xD;
                an open-label fashion off study.&#xD;
&#xD;
      In both strata, treatment continues in the absence of unacceptable toxicity.&#xD;
&#xD;
      In both strata, hot flushes, sleep continuity, sleep quality, and quality of life are&#xD;
      assessed at baseline and at weeks 1, 3, and 6.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 119 patients will be accrued for this study within 20 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep improvement by biologic data and actigraphy data at the end of study treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life by BDI, QOLI, PSI, NCCTG symptom diary, PSQI, MOS SF-36 at the end of study treatment</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">119</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Hot Flashes</condition>
  <condition>Sleep Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>venlafaxine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zolpidem tartrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>management of therapy complications</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  At increased risk of developing breast cancer, meeting 1 of the following criteria:&#xD;
&#xD;
               -  Diagnosis of 1 of the following:&#xD;
&#xD;
                    -  Ductal carcinoma in situ&#xD;
&#xD;
                    -  Invasive breast cancer&#xD;
&#xD;
                    -  Lobular carcinoma in situ&#xD;
&#xD;
                    -  Atypical ductal or lobular hyperplasia&#xD;
&#xD;
                    -  Lobular carcinoma&#xD;
&#xD;
               -  Candidate for breast cancer risk reduction for any of the following:&#xD;
&#xD;
                    -  Predisposing mutation in a breast cancer susceptibility gene&#xD;
&#xD;
                    -  Prior chest radiotherapy for Hodgkin's disease&#xD;
&#xD;
                    -  Gail model score &gt; 1.67% over 5 years&#xD;
&#xD;
          -  Experiencing daytime and nocturnal hot flushes at least 14 times per week within the&#xD;
             past 2 weeks&#xD;
&#xD;
          -  Experiencing sleep disturbance, characterized by the presence of all of the following&#xD;
             for ≥ 1 month:&#xD;
&#xD;
               -  ≥ 3 awakenings per night occurring ≥ 3 nights per week&#xD;
&#xD;
               -  Insomnia impedes daytime function&#xD;
&#xD;
               -  Hot flushes are the primary cause of insomnia (determined at baseline visit)&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 65&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No clinically significant cardiac disease&#xD;
&#xD;
          -  No uncontrolled hypertension within the past 3 months, defined as the following:&#xD;
&#xD;
               -  Diastolic blood pressure &gt; 95 mm Hg on &gt; 1 occasion&#xD;
&#xD;
               -  Systolic blood pressure &gt; 160 mm Hg on &gt; 1 occasion&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  No clinically significant respiratory disease&#xD;
&#xD;
        Psychiatric&#xD;
&#xD;
          -  Beck depression inventory score ≤ 15&#xD;
&#xD;
          -  No active panic or depressive disorder within the past month&#xD;
&#xD;
          -  No lifetime history of bipolar or psychotic disorder&#xD;
&#xD;
          -  No active substance-use disorders, including alcohol and benzodiazepines, within the&#xD;
             past year&#xD;
&#xD;
          -  No suicidal or homicidal ideation&#xD;
&#xD;
          -  No hypomania or mania&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior adverse reaction to venlafaxine or zolpidem&#xD;
&#xD;
          -  None of the following sleep disorders within the past 6 months:&#xD;
&#xD;
               -  Sleep apnea&#xD;
&#xD;
               -  Narcolepsy&#xD;
&#xD;
               -  Periodic limb movement disturbance&#xD;
&#xD;
          -  No abuse or misuse of study medication&#xD;
&#xD;
          -  No daytime sedation that interferes with ability to function&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for 1 month after&#xD;
             study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 3 months since prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 1 month since prior regular use (&gt; 25% of the time) of oral, transdermal, or&#xD;
             injection preparations of androgens, estrogens, or progestins&#xD;
&#xD;
               -  Vaginal suppositories and creams allowed&#xD;
&#xD;
          -  No concurrent regular use of oral, transdermal, or injection preparations of&#xD;
             androgens, estrogens, or progestins&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 3 months since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 1 month since prior regular use (&gt; 25% of the time) of any of the following:&#xD;
&#xD;
               -  Hypnotic agents (e.g., benzodiazepines, zolpidem, zaleplon, trazodone, or&#xD;
                  diphenhydramine)&#xD;
&#xD;
               -  Clonidine&#xD;
&#xD;
          -  More than 1 month since prior antidepressants or other medications that are known to&#xD;
             influence mood &gt; 25% of the time (no serotonin-reuptake inhibitors [SRI] stratum only)&#xD;
&#xD;
          -  Concurrent SRI required provided they were initiated ≥ 1 month ago at or above the&#xD;
             minimum dose, including any of the following (concurrent SRI stratum only):&#xD;
&#xD;
               -  Fluoxetine&#xD;
&#xD;
               -  Paroxetine&#xD;
&#xD;
               -  Paroxetine CR&#xD;
&#xD;
               -  Sertraline&#xD;
&#xD;
               -  Citalopram&#xD;
&#xD;
               -  S-citalopram&#xD;
&#xD;
               -  Venlafaxine&#xD;
&#xD;
               -  Fluvoxamine&#xD;
&#xD;
          -  No concurrent warfarin&#xD;
&#xD;
          -  No concurrent hypnotic agents, clonidine, or antidepressants, or other medications&#xD;
             known to influence sleep, or mood&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hadine Joffe, MD, MSC</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115-6084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>April 27, 2010</last_update_submitted>
  <last_update_submitted_qc>April 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hadine Joffe, MD</name_title>
    <organization>Massachusetts General Hospital</organization>
  </responsible_party>
  <keyword>hot flashes</keyword>
  <keyword>sleep disorders</keyword>
  <keyword>ductal breast carcinoma in situ</keyword>
  <keyword>breast cancer in situ</keyword>
  <keyword>lobular breast carcinoma in situ</keyword>
  <keyword>lobular breast carcinoma</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zolpidem</mesh_term>
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

